FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer

23 January 2020 - Today, the U.S. Food and Drug Administration granted accelerated approval to Tazverik (tazemetostat) for the treatment of ...

Read more →

ICER releases draft evidence report on therapies for sickle cell disease

23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures ...

Read more →

Ready for rescue – new nasally administered glucagon for severe hypoglycaemia available in Canada

23 January 2020 - Eli Lilly Canada introduces Baqsimi, another Canadian innovation to help manage diabetes complications. ...

Read more →

Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with advanced renal cell carcinoma

23 January 2020 - Approval based on results of KEYNOTE-426, Where Keytruda in combination with axitinib reduced the risk of death ...

Read more →

Reimbursement for Repatha to expand treatment options for ASCVD patients

22 January 2020 - Amgen is set to expand treatment options for atherosclerotic cardiovascular disease patients with Repatha, a high-cholesterol treatment, ...

Read more →

Roche wins approval for cancer drug Kadcyla in fast-growing China market

23 January 2020 - Roche said on Wednesday China had approved the import of its Kadcyla drug for breast cancer, another ...

Read more →

Merck strengthens Gonal-f portfolio with approval for 150 IU pen in the European Union

22 January 2020 - New Gonal-f 150 IU pen provides additional flexibility and convenience at every stage of the patients’ stimulation ...

Read more →

NHS patients denied new lung cancer drug after another NICE deadlock

22 January 2020 - Certain untreated lung cancer patients on England’s NHS will have to make do with older drugs ...

Read more →

NICE rejects Janssen’s Stelara on cost efficiency grounds

22 January 2020 - NICE has released a draft guidance not recommending Janssen’s Stelara (ustekinumab) for moderately to severely active ...

Read more →

FDA approves first treatment for thyroid eye disease

21 January 2020 - Today, the U.S. FDA approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a ...

Read more →

European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma

21 January 2020 - Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b. ...

Read more →

European Commission approves Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are transplant eligible

20 January 2020 - Janssen announced today that the European Commission has granted marketing authorisation for Darzalex  (daratumumab) in combination with ...

Read more →

Jazz Pharmaceuticals receives EU marketing authorisation for Sunosi (solriamfetol) for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea

20 January 2020 - Sunosi is the only licensed therapy in Europe for the treatment of excessive daytime sleepiness in adults ...

Read more →

Novartis announces EU approval of Mayzent (siponimod) for adult patients with secondary progressive multiple sclerosis with active disease

20 January 2020 - Mayzent (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple ...

Read more →

NICE encourages further data collection on ‘game changing’ histology independent cancer drugs

17 January 2020 - Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t ...

Read more →